We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ovarian Reserve Tests Prove Poor Predictors of Fertility

By LabMedica International staff writers
Posted on 24 Oct 2017
Print article
Image: A positive pregnancy test; Women with test results indicating low ovarian reserve were no less likely to conceive within six or 12 months of attempts than women whose laboratory tests did not point to a limited egg supply (Photo courtesy of News Health Advisor).
Image: A positive pregnancy test; Women with test results indicating low ovarian reserve were no less likely to conceive within six or 12 months of attempts than women whose laboratory tests did not point to a limited egg supply (Photo courtesy of News Health Advisor).
Tests that measure a woman’s “ovarian reserve” to estimate how many more years of fertility she has have grown increasingly popular, yet despite the lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.

Previous studies have correlated levels of the three hormones with the number of eggs a woman has in her ovaries, known as a measure known as “ovarian reserve.” Studies have suggested that information could be used to predict how well a woman will respond to in vitro fertilization. But in recent years, as more women are delaying pregnancy until later ages, ovarian reserve tests have begun to be used as a way to test for future fertility.

Medical Scientists at the University of North Carolina, (Chapel Hill, NC, USA) carried out a prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of 981 women aged 30 to 44 years without a history of infertility who had been trying to conceive for three months or less, recruited from the local community. Their mean age was 33.3 ± 3.2 years; 77% were white; and 36% were overweight or obese. The primary outcomes were the cumulative probability of conception by six and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle). Conception was defined as a positive pregnancy test result.

The scientists looked the early-follicular-phase serum level of antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH. They found that after adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, 84 women with low AMH values of less than 0.7 ng/mL did not have a significantly different predicted probability of conceiving by six cycles of attempt (65%) compared with 579 women with normal values (62%) or by 12 cycles of attempt (84% versus 75% respectively). The 83 women with high serum FSH values of greater than 10 mIU/mL did not have a significantly different predicted probability of conceiving after six cycles of attempt compared with 654 women with normal values. Similarly, women with high urinary FSH values of greater than 11.5 mIU/mg creatinine did not have a significantly different predicted probability of conceiving and Inhibin B levels were not associated with the probability of conceiving in a given cycle.

The authors concluded that among women aged 30 to 44 years without a history of infertility who had been trying to conceive for three months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility. The study was published on October 10, 2017, in the Journal of the American Medical Association.

Related Links:
University of North Carolina

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.